We envision that pathological samples obtained from patients enrolled in ongoing clinical studies (e.g., the NCT02414139 trial that is evaluating the efficacy of the MET‐TKI capmatinib in NSCLC patients selected for the presence of MET deregulation) will be invaluable for future studies. This evidence concerns the gene MET and non-small cell lung carcinoma.